29.03.20: Not intended for U.S. and UK Media - New study results add to solid evidence for the efficacy and safety of Rivaroxaban in the prevention of venous thromboembolism:

Rivaroxaban significantly reduced risk of major venous thromboembolism following nonmajor orthopaedic surgeryData from PRONOMOS study published in The New England Journal of Medicine and presented during a virtual session of the American College of Cardiology's 69th Annual Scientific Session together with World Congress of Cardiology (ACC.20/WCC Virtual) / The first study to demonstrate that a Factor Xa inhibitor was superior to enoxaparin in reducing risk of major venous thromboembolism in adult patients who have undergone lower limb nonmajor orthopaedic surgery / Bleeding rates were low and not significantly different between the Rivaroxaban and enoxaparin groups / Study is part of an extensive clinical programme exploring Rivaroxaban in people ranging from high risk cancer patients to those having had minor orthopaedic surgerymehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news